Condition: Interaction · Sponsor: Washington State University
The purpose of this pilot study is to gather preliminary data on the (1) contribution of the understudied drug metabolizing enzyme, UDP-glucuronosyltransferase (UGT) 2B17, to the metabolism of a widely used medication, diclofenac, and (2) impact of the UGT2B17 inhibitor and natural product, curcumin, on diclofenac pharmacokinetics. Results will inform future studies aimed to assess the effects of UGT2B17 genetic polymorphisms and co-consumed xenobiotics on the pharmacokinetics and toxicity risk of diclofenac and other UGT2B17 drug substrates.
This description comes directly from the study's public registry record.
Mary F Paine, RPh, PhD · 509-358-7759 · mary.paine@wsu.edu
Siavosh Naji-Talakar, PharmD, MS · 509-358-7739 · s.naji-talakar@wsu.edu
Always discuss trial participation with your own doctor first.
| Washington State University College of Pharmacy and Pharmaceutical Sciences | Spokane, Washington, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06053411